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Abstract
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles following lung transplantation and limits pa-
tients’ long-term outcome. Within the group of emerging CLAD phenotypes, bronchiolitis obliterans syndrome is the most common form 
and observed in up to 75% of lung transplant recipients 10 years after transplantation. Therapeutic options to address BOS are limited and, 
at our center, include modification of immunosuppression, immunomodulation using macrolide antibiotics, the use of statins, leukotriene 
receptor antagonists, and extracorporeal photopheresis. The evidence for most of these therapy options is derived from case reports or 
small, descriptive studies, whereas controlled trials are yet to be conducted. In the context of an illustrative case report, we review hereby 
the current literature regarding these different treatment options. 
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INTRODUCTION
The development of chronic lung allograft dysfunction (CLAD) is one of the major obstacles follow-
ing lung transplantation and limits patients’ long-term outcome. Within the group of emerging CLAD 
phenotypes, bronchiolitis obliterans syndrome is the most common form and observed in up to 75% 
of lung transplant recipients 10 years after transplantation. We briefly present a typical case that illus-
trates many aspects encountered in the context of CLAD and CLAD management.
A 50-year-old patient with end-stage chronic obstructive pulmonary disease (COPD) complicated by 
frequent exacerbations underwent bilateral sequential lung transplantation. The patient was com-
menced on a standard immunosuppressive regimen with cyclosporine, mycophenolate mofetil, and 
corticosteroids. Anti-infective prophylaxis included trimethoprim/sulfamethoxazole, itraconazole, 
and, in the context of an intermediate risk constellation for cytomegalovirus (CMV donor negative/
recipient positive), valganciclovir. Since the patient developed post-transplant hypo-gammaglobu-
linemia (IgG 5.1 g/L; normal range 7.0–16.0 g/L), immunoglobulins were substituted intravenously 
on a regular basis. The early post-operative course was uneventful, and the patient was discharged 
from hospital at day 27 after transplantation. 
Initially, the patient was seen on a weekly basis in the outpatient department and, due to an 
excellent allograft function and lack of infectious complications, this interval was further pro-
longed to a period of four to six weeks. Surveillance bronchoscopies were performed at month 
2, 3, 4, and 6 after transplantation. Endobronchial inspection and differential cellularity of bron-
choalveolar lavage were normal (i.e., at month 4 after lung transplantation: cell count 220/µL, 
macrophages 94%, neutrophil granulocytes 3.5%, lymphocytes 3%). Transbronchial biopsies did 
not show signs of infection or acute cellular rejection (ISHLT A0B0). Allograft function peaked 3 
months after transplantation with a forced expiratory volume in 1 s (FEV1) of 4250 mL (120% of 
predicted).
Eleven months after transplantation, the patient presented with 
symptoms of an upper respiratory tract infection and signs of inflam-
mation (C-reactive protein 22 mg/L, leukocyte count 11 G/L). Lung 
function testing showed a significant decrease of FEV1 to 3120 mL 
(73% of best FEV1, FEV1/FVC 81%). However, pharyngeal swabs did 
not detect any pathogens (normal oral microflora, negative virology 
multiplex PCR). The patient was empirically treated with piperacillin/
tazobactam. Since symptoms and lung function recovered incom-
pletely, chest computed tomography (CT) and bronchoscopy were 
performed. The CT findings were unremarkable, but transbronchial 
biopsies revealed cellular allograft rejection (ISHLT A2B0), probably 
triggered by the precedent respiratory tract infection. Pulse steroid 
therapy (1 g methyl-prednisolone intravenously for 3 days, followed 
by an oral taper) was administered and the calcineurin-inhibitor ther-
apy was switched from cyclosporine to tacrolimus. Since transbron-
chial biopsy was complicated by the development of an iatrogenic 
pneumothorax requiring a chest drain insertion, lung function moni-
toring had to be paused until complete radiological resolution. Bron-
choscopy follow-up 4 weeks later showed no evidence of an ongoing 
acute cellular rejection (ISHLT A0B0). However, lung function deteri-
orated further with an obstructive pattern in lung function testing. 
Chest CT, which had been unremarkable at the time of acute cellular 
rejection, now showed tree-in-bud lesions and progressive air trap-
ping, compatible with the development of bronchiolitis obliterans 
syndrome (BOS, classification displayed in Table 1). Macrolide ther-
apy with azithromycin was established with an immunomodulatory 
dose (250 mg three times weekly) and extracorporeal photopheresis 
(ECP) was started subsequently thereafter. However, ECP had to be 
stopped after 8 treatment cycles since the health insurance compa-
ny denied further financial reimbursement. Thus, treatment with the 
leukotriene receptor antagonist montelukast (10 mg once daily) and 
the HMG-CoA-reductase inhibitor pravastatin was established. Lung 
function further decreased despite all interventions (nadir of FEV1 
610 mL, 14% of best FEV1, and FEV1/FVC 40%). Due to an excellent 
clinical course during the first year post-transplantation and no ev-
idence for failure of other organ systems other than severe chronic 
lung allograft dysfunction, the patient was evaluated for re-trans-
plantation and listed 18 months after primary transplantation. Lung 
functional course and therapeutic interventions are summarized in 
Figure 1.
Long-term success of lung transplantation, as exemplified by this 
case report, is mainly limited by the development of chronic lung 
allograft dysfunction (CLAD). Different CLAD phenotypes have re-
cently been described (1, 2). However, “classical” bronchiolitis obliter-
ans syndrome (BOS) remains the most common form of CLAD and is 
observed in about 50% of lung transplant patients after 5 years and 
in more than 75% of patients after 10 years following lung transplan-
tation (3). This article aims to review current practice and published 
evidence (Table 2) for treatment of BOS.
Therapeutic Options
Modification of Immunosuppression
In the absence of contraindications, all lung transplant patients at 
our center receive a triple immunosuppressant therapy consisting of 
calcineurin inhibitors (CNIs), an antimetabolite, and corticosteroids. 
Inhibition of calcineurin interferes with the synthesis of interleukins, 
and as such, with the activation of T-lymphocytes. Cyclosporine and 
tacrolimus are the most commonly used CNIs. Whether tacrolimus is 
more efficient in preventing episodes of acute rejections and wheth-
er cyclosporine or tacrolimus is the preferred agent to delay the de-
velopment of BOS is a controversial issue (4).
A prospective trial showed significant reduction in the develop-
ment of BOS in the tacrolimus group as compared to the cyclospo-
rine group (38%) (5). However, this effect could not be confirmed at 
long-term follow-up. Similarly, Zuckermann et al. (6) could not show 
significant long-term differences between tacrolimus and cyclospo-
rine therapy. Since a trend towards a decreased rejection rate was 
observed in patients on tacrolimus, the authors suggested the use of 
tacrolimus for patients at high risk for the development of allograft 
rejection. Along this line, Hachem et al. (7) reported a significant 
difference between patients treated with tacrolimus and cyclospo-
rine. In tacrolimus-treated patients, the incidence of acute cellular 
rejection and lymphocytic bronchiolitis was significantly lower and 
a trend towards less development of BOS was observed. Treede et 
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Table 1. BOS classification (based on spirometry)
BOS Grade %FEV1 of best post-transplant FEV1
0 >90
0-p 81-90
1 66-80
2 50-65
3 <50
BOS: Bronchiolitis obliterans syndrome; FEV1: forced expiratory volume in 1 s
Figure 1. Illustrative course in a lung transplant recipient develo-
ping bronchiolitis obliterans syndrome (BOS)
Major complications, infections, lung functional decline, BOS 
severity, and treatment are shown. P (in red box) denotes devel-
opment of Pneumothorax, I (in red circle) pulmonary infections. 
Infectious complications include Haemophilus influenzae, rhinovi-
rus, parainfluenzavirus, and Pseudomonas aeruginosa (according 
to chronologous detection)
CS: Corticosteroids; CNI switch: calcineurin-inhibitor switch; ECP: extra-
corporeal photopheresis; LTRA: lung transplantation; HMG-CoA-I: 3-hy-
droxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin 
therapy)
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al. (8) found a significantly lower incidence of BOS in patients treated 
with tacrolimus than with cyclosporine over a period of 3 years. The 
underlying mechanisms that explain the lower rate of BOS in patients 
treated with tacrolimus remain unclear but, at least in part, might be 
due to the observation that mesenchymal cells obtained from BOS 
patients that were converted from closporine to tacrolimus express 
reduced levels of collagen and other extracellular matrix proteins fol-
lowing the CNI switch (9). 
 
Although these studies address the potential benefits and risks of 
tacrolimus versus cyclosporine used immediately after transplanta-
tion, the question whether patients should be switched from cyclo-
sporine to tacrolimus following the development of BOS is even less 
resolved. In this context, several small retrospective studies analyzed 
the specific benefits of such conversion. Our literature search iden-
tified five small studies (5, 10-13) in which the majority of patients 
who switched to tacrolimus showed reduced FEV1 decline. In the 
largest retrospective study so far, Sarahrudi et al. (14) analyzed 244 
patients from 13 institutions and reported fewer acute cellular rejec-
tion episodes and a reduction of FEV1 decline in BOS patients. The 
benefits of CNI conversion to tacrolimus could also be observed in 
prospective studies. Fieguth et al. (15) showed FEV1 improvement in 
6 of 7 new-onset BOS patients, and data of Borro et al. (16) showed an 
overall reduction of FEV1 decline in 79 BOS patients.
Based on these studies, CNI switch is commonly practiced at many 
institutions after the development of BOS, but randomized clinical 
trials are yet to be conducted. Future clinical studies have also to 
evaluate the best timing for a CNI switch. 
Macrolide Antibiotics
Macrolide antibiotics, normally used as antimicrobial treatment, 
have additional immunomodulatory properties: It is known that 
even in low doses, azithromycin and clarithromycin increase the 
phagocytosis of apoptotic cells by alveolar macrophages and in-
hibit the production and release of pro-inflammatory cytokines 
(including IL-8 and tumor necrosis factor [TNF] alpha). Moreover, 
macrolides increase apoptosis of neutrophils and inhibit neutro-
phil adhesion to epithelial cells (17). The integrity of the epithelial 
barrier plays a major role in the defense of pathogens. Within the 
airways of the lung, this barrier is formed by a mucus layer, cellular 
junctions, cellular polarity, and a chemical defense. It was shown 
that macrolides modulate the expression of mucin genes and in-
teract with protein production. Clarithromycin, for example, was 
found to inhibit hyper- and metaplasia of goblet cells. Whether 
macrolides have a direct impact on ion movement and altered cel-
lular polarity due to abnormal mucus clearance or cellular junctions 
is unclear. In this context, azithromycin increased the production of 
cell occlusion proteins suggesting stabilization of the physical bar-
rier. However, a consistent effect of macrolides on defensins could 
not be observed (18).
Experimental evidence for macrolide therapy in lung transplantation 
was obtained in a rat model using tracheal allografts. Remund et al. 
(19) analyzed the progression of BOS in these allografts and pre-emp-
tive treatment with clarithromycin, probably by reduced expression 
of TNF-alpha and interferon (IFN)-gamma, completely prevented the 
tracheal lumen from obliteration.
The use of macrolide therapies in lung transplant recipients with 
CLAD/BOS was first suggested by two open-label pilot studies (20, 
21). These studies, performed in a small number of lung transplant 
recipients, investigated whether the beneficial immunomodulatory 
effect of macrolide therapy observed in patients with cystic fibrosis 
and pan-bronchiolitis can also be observed in patients with estab-
lished BOS. The results for this treatment modality were promising 
and suggested significant improvement of mean FEV1 after 12 and 
36 weeks of treatment, respectively. 
Further studies confirmed the beneficial effect of macrolides in a 
cohort of lung transplant patients with BOS observing an increase 
of FEV1 in 30% of treated patients after six months (22). A recent 
controlled trial randomized BOS patients to receive azithromycin 
or placebo. Comparison of lung function 12 weeks after beginning 
this treatment showed a significant improvement of FEV1 with azi-
thromycin (mean 35 mL) (23). Conversely, one follow-up trial did 
not detect improvements in lung function after the introduction 
of macrolide therapy and concluded that macrolides have no role 
in the treatment of the declining lung function due to chronic re-
jection (24).
Benden and Boehler (25) reported the experience with clarithromy-
cin therapy in 31 lung transplant recipients followed for 12 months. 
Improvement of lung function was observed in 12 patients. This 
study suggested that the two macrolide regimens are of similiar ef-
ficacy. However, the magnitude of interactions and the fact that a 
substantially reduced number of pills required when using azithro-
mycin as compared to clarithromycin might explain the preference of 
most centers for azithromycin in the context of immunomodulation 
for lung transplant recipients. 
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Table 2. Overview of available evidence by study design for CLAD/BOS
RCT Observational Experimental Pilot study Case report
CNI Switch 4 6 2
Macrolide antibiotics 2 2 1 2
HMG-CoA-Inhibition 2 2
Leukotriene receptor antagonist 1
Extracorporeal Photopheresis 8 1
BOS: Bronchiolitis obliterans syndrome; CLAD: chronic lung allograft dysfunction; CNI: calcineurin inhibitor; HMG-CoA-inhibition: 3-hydroxy-3-methylglu-
taryl coenzyme A inhibition; RCT: randomized controlled trial
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Based on these data, it is common practice and suggested by cur-
rent guidelines to establish macrolide therapy in immunomodula-
tory doses at onset of BOS as evidenced by lung functional decline 
and/or the development of air trapping in expiratory CT chest im-
ages (1). Since it is of interest not only to treat and stabilize CLAD/
BOS but rather to prevent its development, the question whether 
macrolide therapy should be established early post-transplant is of 
importance. In this context, the study by Vos et al. (26) is of major 
relevance. This randomized controlled trial conducted in a group of 
83 lung transplant patients evaluated whether prophylactic azithro-
mycin commenced at hospital discharge after transplantation might 
prevent the development of CLAD/BOS/chronic rejection measured 
as BOS-free survival 2 years after transplantation. These data showed 
a significantly lower occurrence of chronic rejection in patients on 
prophylactic azithromycin than in patients without it. 
Moreover, macrolide therapy is used in lung transplant patients 
with the recently described phenotype of neutrophilic reversible al-
lograft dysfunction (NRAD). This form of acute allograft dysfunction 
is characterized by neutrophilic alveolitis in the absence of infection. 
Patients with NRAD show an excellent response to azithromycin in 
therapeutic doses (27). However, a detailed discussion of this type of 
acute allograft dysfunction is beyond the scope of this review.
HMG-CoA Inhibition
Acting through inhibition of the 3-hydroxy-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase, statins are widely used to reduce 
blood cholesterol levels. For this indication, statins are also em-
ployed in lung transplant recipients, in which, according to registry 
data, dyslipidemia is observed in >20% of patients after 1 year and 
in >50% after 5 years following transplantation (28). However, statins 
have also been associated with immunomodulation and anti-inflam-
matory mechanisms. These pleiotropic effects are of special inter-
est in recipients of solid organs. In this context, Johnson et al. (29) 
compared the outcomes of 39 lung transplant patients treated with 
statins and 161 patients without such a treatment. This study showed 
an increased overall survival of patients under statin treatment when 
followed-up for 6 years but was limited by its retrospective design. 
In study patients, both the incidence of acute allograft rejection and 
the development of BOS were less frequently observed. The reduced 
predominance of neutrophilic cells in bronchoalveolar lavage fluid 
in statin-treated patients was interpreted as independent indicator 
of statin efficacy to prevent allograft dysfunction. Of interest, none 
of the patients that received early anti-dyslipidemic treatment-i.e., 
within the first post-transplant year-were diagnosed with BOS during 
the observation phase. 
Another retrospective study performed a propensity-matched anal-
ysis of 75 patients on pravastatin therapy and a control group of 340 
lung transplant patients without pravastatin. In line with the data 
from Johnson et al, statin treatment was found to delay the develop-
ment and severity of BOS. Moreover, higher FEV1 volumes were mea-
sured in statin-treated patients during the whole follow-up period 
and statin treatment prolonged the survival time significantly (30).
Two experimental studies using rat models might explain the immu-
nomodulatory and immunosuppressive effects of statins: Ropponen 
et al. (31) studied the effects of Simvastatin on tracheal allograft 
recipients and observed early epithelial recovery due to enhanced 
cell proliferation under statin treatment and reduced development 
of obliterative airway disease. Another study compared the postop-
erative development of bronchiolitis obliterans in single lung trans-
planted animals with and without pravastatin therapy (32). Although 
allograft rejection occurred in all transplanted animals, pravastatin 
treated animals rejected the allograft significantly later than untreat-
ed rats. In both studies, statins were found to reduce significantly the 
amount of T-lymphocytes invading the allograft. 
The above studies indicate beneficial effects of statin therapy for lung 
transplant patients independent of the presence of dyslipidemia. 
Since these effects appear to be most promising when established 
early after transplantation, controlled trials are needed to answer the 
question whether all lung transplant recipients should receive statins 
as part of their immediate post-transplant treatment regimen to pre-
vent allograft rejection and the development of BOS. 
Leukotriene Receptor Antagonist
Cysteinyl leukotrienes play an essential role in bronchoconstric-
tion by increasing bronchial hyperreactivity and attracting eosino-
phils and neutrophils to the lamina propria (33). Additional effects 
of leukotrienes include increased vascular permeability and mucus 
hypersecretion. Leukotriene receptor antagonists (i.e., montelukast) 
suppress this pathway and, as such, are used as anti-inflammatory 
agents in asthma patients. Promising effects of montelukast therapy 
have also been observed on lung function in patients with pulmo-
nary graft-versus-host (GvHD) disease (34). Since the lung pathology 
in GvHD and CLAD following lung transplantation share pathogenet-
ic and morphologic features, Verleden et al. (35) conducted a pilot 
study with montelukast in azithromycin non-responsive CLAD/BOS 
patients. In eleven patients, treatment with montelukast resulted in 
a deceleration of the monthly FEV1 decline from 112 mL (±26 mL) 
before to 13 mL (±13 mL)/month after initiation of treatment was ob-
served, whereas no change in the control group occurred. 
While these data are promising and support the use of montelukast 
in LTR developing BOS, controlled clinical trials should be conduct-
ed to corroborate the evidence of leukotriene receptor antagonist 
therapy. In this context, the results of a first randomized controlled 
trial using montelukast in lung transplant patients with CLAD have 
recently been presented and appear to confirm these findings (36).
Extracorporeal Photopheresis
Extracorporeal photopheresis (ECP) is leukopheresis-based photo-
therapy by which leukocytes are exposed to a photosensitizing agent 
and irradiation with UVA light outside of the patient. The underlying 
mechanisms of ECP have not fully been elucidated to date. Howev-
er, major factors include the induction of apoptosis, modulation of T 
regulatory cells, and induction of immune tolerance (37-39).
Successful treatment of cutaneous T-cell lymphoma and acute 
cardiac allograft rejection by ECP encouraged Slovis et al. (40) in 
1995 to treat six patients with CLAD resulting in stabilization of 
lung function in five cases. Further studies confirmed these data in 
a small number of patients (41, 42) while the study by Villanueva et 
al. (43) suggested a better effect of ECP in patients with early BOS. 
These data might be subjected to a lead time bias but still empha-
size the importance of escalating therapy to prevent the progres-
sion of BOS/CLAD early. 
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Benden et al. (44) reported the experiences with ECP for patients with 
BOS and recurrent acute cellular rejection episodes. Twelve patients di-
agnosed with BOS showed deceleration in the monthly decline of FEV1 
from 112 mL/month before the treatment to 12 mL/month after ECP 
initiation. The largest retrospective study was conducted by Morrell et 
al. (45) with 60 patients followed for 7 years. Similarly, to the data re-
ported by Benden et al. (44) this study observed a significant reduction 
in the monthly decrease of FEV1 (116 mL/month before treatment as 
compared to 28 mL/month after ECP). In 25% of ECP-treated patients, 
an increase in FEV1 was reported. The first prospective study was con-
ducted by Jaksch et al. (46) comparing 143 patients under standard-
ized treatment with 51 patients that were additionally treated with 
ECP. In 18% of ECP-treated patients, a sustained improvement of FEV1 
for more than 1 year was observed, in 12% lung functional improve-
ment was found for 3 to 6 months and in 31% of patients’ stabilization 
of lung function could be achieved. Of interest, differences between 
responders to ECP therapy as compared to non-responders included 
time of onset of BOS (early posttransplant development of BOS), ki-
netics of lung functional decline (slower decrease of lung function at 
the beginning of BOS) and BOS severity (lower BOS grade). A study by 
the Hannover group investigated the effects of ECP on different phe-
notypes of CLAD suggesting that patients with restrictive allograft 
syndrome (RAS), for example, respond less to ECP than patients with 
neutrophilic CLAD (47). Conversely, a recent study performed by Del 
Fante et al. (48) reported a 10 years follow-up of 48 CLAD patients treat-
ed with ECP, and in these patients, no association between FEV1 de-
cline pattern and failure of ECP therapy or CLAD phenotype was found. 
However, the authors observed different survival rates of patients with 
different BOS phenotypes. This data is in line with our own experience 
(49). Moreover, a short time interval between transplantation and 
CLAD onset was correlated with a higher risk of ECP failure.
These findings imply that certain CLAD phenotypes (e.g., RAS) and 
faster initial progression of CLAD/BOS have a high failure risk for ECP 
treatment. Surprisingly, in this study, the failure rate of ECP patients 
could not be associated with poorer survival rates. Whether CLAD 
phenotypes have any role in predicting response to ECP therapy and 
survival of patients remains unclear. Current evidence supports our 
center’s practice to offer ECP treatment to all CLAD patients indepen-
dent of phenotypes as early as indicated; i.e. when other treatment 
options fail to show beneficial effects. 
CONCLUSION
The development of CLAD/BOS remains one of the major obstacles 
following lung transplantation limiting its long-term success. In this 
review, we discussed the evidence for therapeutic options available 
to date to address BOS, including modification of immunosuppres-
sion, immunomodulation by macrolide antibiotics, use of statins and 
leukotriene receptor antagonists, and ECP. A summarizing algorithm 
to diagnose and treat BOS is provided in Figure 2 (1, 50). While some 
of these therapies used alone or in combination have shown bene-
ficial effects, no intervention prevents or reverses CLAD/BOS and, as 
such, the development of novel therapies is urgently needed.
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